Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

NCT06164730 is registered in ClinicalTrials.gov with Verve Therapeutics, Inc. as lead sponsor.

NCT NCT06164730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06164730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
Lead sponsor
Verve Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2024
Completion date
October 31, 2027
Enrollment
85 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia, premature coronary heart disease